

PATENT /

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	) Confirmation No. 4098
Elizabeth JAFFEE, et al.	) Examiner: L. Bristol
Serial No. 10/618,088	) Group Art Unit: 1643
Filed: July 14, 2003	) Atty. Dkt. No. 001107.00363
For: MESOTHELIN VACCINES AND MODEL SYSTEMS	) ) )

## RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents c/o Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In response to the Office Action mailed May 12, 2006, Applicants elect for prosecution in this application Group 5 drawn to methods for inducing a T-cell response to a mesothelin-overexpressing tumor in a patient with or having had the tumor comprising administering a vaccine comprising a polynucleotide encoding a polypeptide comprising an MHC Class I-binding epitope of mesothelin. This Group encompasses claims 22-38 and 111.

Applicants further elect with respect to species pancreatic cancer; VLPLTVAEV (SEQ ID NO:2) and Listeria monocytogenes.

Claims which read on the elected species are: 22-24, 26-38, and 111.

A petition for a three-month extension of time accompanies this paper. No additional fee is believed due in connection with this response. However, should the Patent and Trademark Office determine that a fee is required, please charge our Deposit Account No. 19-0733.

Respectfully submitted,

Date: September 11, 2006

By:

Sarah A. Kagan Registration No. 32,141

Banner & Witcoff, Ltd. Customer No. 22907